Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …

Background Safe and effective oral treatments are needed to improve clinical outcomes for
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small …

Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …

Background Molnupiravir is an oral prodrug of β-d-N4-hydroxycytidine, active against SARS-
CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe …

Purpose Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …

Background The effects of molnupiravir in treating patients with non-severe COVID-19
remain uncertain. Objectives To evaluate the efficacy and safety of molnupiravir in adult …

Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Background Molnupiravir was granted emergency use authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …

Background Molnupiravir is an oral antiviral drug that received Emergency Use
Authorization in three countries for the treatment of mild COVID-19. The aim of this …

Background: In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction
in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk …